Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
doi: 10.1002/hsr2.2004
As with other incretin-based therapies, the most commonly reported side effects of retatrutide in clinical trials are gastrointestinal in nature
There are three categories of GLP-1 medications relevant to Canadian patients: Pure GLP-1 receptor agonists These medications activate only the GLP-1 receptor
"So the question is does it correlate to the medication [or] does it correlate to the patient population?" he said
The liver fat reduction data from Phase 2 (86% at 12mg) far exceeds what has been reported for other GLP-1 or dual-agonist drugs
Retatrutide is an unlicensed investigational tri-agonist targeting GLP-1, GIP, and glucagon receptors
US$ 24.81
US$ 25.23
US$ 26.94
